The effect of angostifolia in patients with Cirrhosis
Phase 3
- Conditions
- Other and unspecified cirrhosis of liveriver cirrhosis.
- Registration Number
- IRCT20100223003408N4
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Person with Cirrhosis
Age between 18 to 60 years
Exclusion Criteria
Diabetes
Hypothyroidism or hyperthyroidism
Kidney disease
Lung disease
Cardiovascular disease
Smoking
Alcohol and tobacco consumption
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does angostifolia modulate to reduce inflammatory markers in cirrhosis patients in IRCT20100223003408N4?
How does angostifolia supplementation compare to standard-of-care in improving liver enzyme profiles in cirrhosis patients in IRCT20100223003408N4?
Which plasma inflammatory biomarkers are associated with angostifolia efficacy in cirrhosis management in IRCT20100223003408N4?
What are the potential adverse events of angostifolia in cirrhosis patients in IRCT20100223003408N4 and how are they managed?
Are there other herbal compounds synergistic with angostifolia in reducing hepatic inflammation in cirrhosis in IRCT20100223003408N4?